{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:02:32Z","timestamp":1787868152976,"version":"build-2784847793"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ejpb.2021.02.015","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T03:34:13Z","timestamp":1616556853000},"page":"1-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"special_numbering":"C","title":["Design, development and in-vitro\/in-vivo evaluation of intranasally delivered Rivastigmine and N-Acetyl Cysteine loaded bifunctional niosomes for applications in combinative treatment of Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"163","author":[{"given":"Pratik","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Rawtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejas","family":"Barot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejpb.2021.02.015_b0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejpb.2021.02.015_b0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1756285612461679","article-title":"Current and future treatments for Alzheimer\u2019s disease","volume":"6","author":"Yiannopoulou","year":"2013","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.ejpb.2021.02.015_b0015","doi-asserted-by":"crossref","DOI":"10.1039\/D0NR04037A","article-title":"Bi-functional sterically hindered phenol lipid-based delivery systems as potential multi-target agents against Alzheimer's disease via intranasal route","author":"Burilova","year":"2020","journal-title":"Nanoscale"},{"issue":"02","key":"10.1016\/j.ejpb.2021.02.015_b0020","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0039-1678581","article-title":"Current and future treatments in Alzheimer\u2019s disease","volume":"39","author":"Atri","year":"2019","journal-title":"Semin. Neurol."},{"issue":"1","key":"10.1016\/j.ejpb.2021.02.015_b0025","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jep.2011.10.042","article-title":"Investigation of the in vitro and ex vivo acetylcholinesterase and antioxidant activities of traditionally used Lycopodium species from South America on alkaloid extracts","volume":"139","author":"Konrath","year":"2012","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejpb.2021.02.015_b0030","article-title":"Alzheimer's disease and its potential alternative therapeutics","author":"Kisby","year":"2019","journal-title":"J. Alzheimer's Dis. Parkinsonism"},{"issue":"8","key":"10.1016\/j.ejpb.2021.02.015_b0035","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1517\/13543776.2012.701620","article-title":"Acetylcholinesterase inhibitors: a patent review (2008 - present)","volume":"22","author":"Pohanka","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejpb.2021.02.015_b0040","doi-asserted-by":"crossref","DOI":"10.55782\/ane-2004-1495","article-title":"Alzheimer\u2019s disease and acetylcholine receptors","author":"Kihara","year":"2004","journal-title":"Acta Neurobiol. Exp. (Wars)"},{"key":"10.1016\/j.ejpb.2021.02.015_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2017.00744","article-title":"Systematic review of human and animal studies examining the efficacy and safety of N-acetylcysteine (NAC) and N-Acetylcysteine Amide (NACA) in traumatic brain injury: impact on neurofunctional outcome and biomarkers of oxidative stress and inflammation","volume":"8","author":"Bhatti","year":"2018","journal-title":"Front. Neurol."},{"issue":"12","key":"10.1016\/j.ejpb.2021.02.015_b0050","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.3390\/molecules23123305","article-title":"Overview on the effects of N-acetylcysteine in neurodegenerative diseases","volume":"23","author":"Tardiolo","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2021.02.015_b0055","doi-asserted-by":"crossref","DOI":"10.14283\/jpad.2017.22","article-title":"Evaluation of the neuroprotective potential of N-acetylcysteine for prevention and treatment of cognitive aging and dementia","author":"Hara","year":"2017","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"issue":"3","key":"10.1016\/j.ejpb.2021.02.015_b0060","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1124\/jpet.119.258152","article-title":"Nose-to-brain delivery","volume":"370","author":"Wang","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.ejpb.2021.02.015_b0065","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/pharmaceutics10030116","article-title":"Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa","volume":"10","author":"G\u00e4nger","year":"2018","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.ejpb.2021.02.015_b0070","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3390\/pharmaceutics11100540","article-title":"Liposomal formulations for nose-to-brain delivery: recent advances and future perspectives","volume":"11","author":"Hong","year":"2019","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ejpb.2021.02.015_b0075","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-018-0351-4","article-title":"Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy","volume":"16","author":"Alemi","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejpb.2021.02.015_b0080","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.colsurfa.2019.01.004","article-title":"Formulation and optimization of long acting dual niosomes using Box-Behnken experimental design method for combinative delivery of Ethionamide and D-cycloserine in Tuberculosis treatment","volume":"565","author":"Kulkarni","year":"2019","journal-title":"Colloids Surfaces A Physicochem. Eng. Asp."},{"key":"10.1016\/j.ejpb.2021.02.015_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2019.03.020","article-title":"Application of box-behnken design in the preparation, optimization, and in vitro evaluation of self-assembly\u2013based tamoxifen- and doxorubicin-loaded and dual drug-loaded niosomes for combinatorial breast cancer treatment","author":"Kulkarni","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2021.02.015_b0090","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cis.2013.11.018","article-title":"Niosomes from 80s to present: the state of the art","volume":"205","author":"Marianecci","year":"2014","journal-title":"Adv. Colloid Interface Sci."},{"issue":"3","key":"10.1016\/j.ejpb.2021.02.015_b0095","doi-asserted-by":"crossref","DOI":"10.5101\/nbe.v9i3.p242-248","article-title":"Formulation and evaluation of etoricoxib niosomes by thin film hydration technique and ether injection method","volume":"9","author":"Ravalika","year":"2017","journal-title":"Nano Biomed. Eng."},{"issue":"3","key":"10.1016\/j.ejpb.2021.02.015_b0100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40005-017-0331-y","article-title":"Artemisinin-loaded niosome and pegylated niosome: physico-chemical characterization and effects on MCF-7 cell proliferation","volume":"48","author":"Asgharkhani","year":"2018","journal-title":"J. Pharm. Investig."},{"issue":"3","key":"10.1016\/j.ejpb.2021.02.015_b0105","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3109\/08982104.2014.881850","article-title":"Preparation, characterization and evaluation of novel elastic nano-sized niosomes (ethoniosomes) for ocular delivery of prednisolone","volume":"24","author":"Gaafar","year":"2014","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ejpb.2021.02.015_b0110","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.msec.2016.07.043","article-title":"Formulation and optimization of niosomes for topical diacerein delivery using 3-factor, 3-level Box-Behnken design for the management of psoriasis","volume":"69","author":"Moghddam","year":"2016","journal-title":"Mater. Sci. Eng., C"},{"issue":"1-2","key":"10.1016\/j.ejpb.2021.02.015_b0115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijpharm.2015.03.020","article-title":"Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study","volume":"485","author":"Abdelbary","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.ejpb.2021.02.015_b0120","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-009-9325-z","article-title":"Enhanced oral bioavailability of griseofulvin via niosomes","volume":"10","author":"Jadon","year":"2009","journal-title":"AAPS PharmSciTech."},{"issue":"2","key":"10.1016\/j.ejpb.2021.02.015_b0125","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/pharmaceutics10020038","article-title":"Chitosan glutamate-coated niosomes: a proposal for nose-to-brain delivery","volume":"10","author":"Rinaldi","year":"2018","journal-title":"Pharmaceutics"},{"issue":"1-2","key":"10.1016\/j.ejpb.2021.02.015_b0130","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijpharm.2018.06.026","article-title":"Lipidation of polyethylenimine-based polyplex increases serum stability of bioengineered RNAi agents and offers more consistent tumoral gene knockdown in vivo","volume":"547","author":"Zhang","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.ejpb.2021.02.015_b0135","doi-asserted-by":"crossref","DOI":"10.1208\/pt0804086","article-title":"Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level Box-Behnken design","volume":"8","author":"Solanki","year":"2007","journal-title":"AAPS PharmSciTech."},{"issue":"1","key":"10.1016\/j.ejpb.2021.02.015_b0140","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijpharm.2013.09.011","article-title":"Alkyl glucopyranoside-based niosomes containing methotrexate for pharmaceutical applications: evaluation of physico-chemical and biological properties","volume":"458","author":"Muzzalupo","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2021.02.015_b0145","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1006\/jcis.2002.8399","article-title":"Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol","volume":"251","author":"Devaraj","year":"2002","journal-title":"J. Colloid Interface Sci."},{"issue":"1-2","key":"10.1016\/j.ejpb.2021.02.015_b0150","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijpharm.2005.09.023","article-title":"Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide","volume":"306","author":"Guinedi","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2021.02.015_b0155","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejps.2018.06.025","article-title":"Liposils: an effective strategy for stabilizing Paclitaxel loaded liposomes by surface coating with silica","volume":"122","author":"Ingle","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2021.02.015_b0160","article-title":"E2524\u201308(2013) standard test method for analysis of hemolytic properties of nanoparticles","author":"S.T. Method","year":"2013","journal-title":"ASTM Int."},{"issue":"1","key":"10.1016\/j.ejpb.2021.02.015_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086804","article-title":"In vitro screening for anti-cholinesterase and antioxidant activity of methanolic extracts of ayurvedic medicinal plants used for cognitive disorders","volume":"9","author":"Mathew","year":"2014","journal-title":"PLoS ONE"},{"issue":"5-6","key":"10.1016\/j.ejpb.2021.02.015_b0170","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1515\/znc-2004-5-610","article-title":"Free radical scavengers and antioxidants from Tagetes mendocina","volume":"59","author":"Schmeda-Hirschmann","year":"2004","journal-title":"Zeitschrift Fur Naturforsch. \u2013 Sect. C J. Biosci."},{"issue":"1-2","key":"10.1016\/j.ejpb.2021.02.015_b0175","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejps.2012.10.029","article-title":"Ex vivo permeation characteristics of venlafaxine through sheep nasal mucosa","volume":"48","author":"Pund","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2021.02.015_b0180","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1080\/10717544.2017.1309476","article-title":"Electrosteric stealth rivastigmine loaded liposomes for brain targeting: Preparation, characterization, ex vivo, bio-distribution and in vivo pharmacokinetic studies","volume":"24","author":"Nageeb El-Helaly","year":"2017","journal-title":"Drug Deliv."},{"issue":"12","key":"10.1016\/j.ejpb.2021.02.015_b0185","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1016\/j.xphs.2017.08.024","article-title":"Nose to brain delivery of rivastigmine by in situ gelling cationic nanostructured lipid carriers: enhanced brain distribution and pharmacodynamics","volume":"106","author":"Wavikar","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejpb.2021.02.015_b0190","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2478\/v10007-008-0014-3","article-title":"A study of rivastigmine liposomes for delivery into the brain through intranasal route","volume":"58","author":"Arumugam","year":"2008","journal-title":"Acta Pharm."},{"issue":"4","key":"10.1016\/j.ejpb.2021.02.015_b0195","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4103\/0973-8398.76752","article-title":"Effect of formulation and processing variables on the particle size of sorbitan monopalmitate niosomes","volume":"4","author":"Essa","year":"2010","journal-title":"Asian J. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2021.02.015_b0200","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejpb.2006.09.001","article-title":"Release modulating hydrophilic matrix systems of losartan potassium: optimization of formulation using statistical experimental design","volume":"66","author":"Chopra","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"4","key":"10.1016\/j.ejpb.2021.02.015_b0205","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.colsurfb.2004.09.004","article-title":"Studies on the encapsulation of diclofenac in small unilamellar liposomes of soya phosphatidylcholine","volume":"39","author":"Lopes","year":"2004","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"10.1016\/j.ejpb.2021.02.015_b0210","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.msec.2015.06.049","article-title":"Self-degrading niosomes for encapsulation of hydrophilic and hydrophobic drugs: an efficient carrier for cancer multi-drug delivery","volume":"56","author":"Sharma","year":"2015","journal-title":"Mater. Sci. Eng., C"},{"issue":"8","key":"10.1016\/j.ejpb.2021.02.015_b0215","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1080\/03639045.2017.1310224","article-title":"Enhanced oral bioavailability and sustained delivery of glimepiride via niosomal encapsulation: in-vitro characterization and in-vivo evaluation","volume":"43","author":"Mohsen","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"1-2","key":"10.1016\/j.ejpb.2021.02.015_b0220","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijpharm.2010.05.005","article-title":"Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability","volume":"394","author":"Zhuang","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.ejpb.2021.02.015_b0225","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/jps.21944","article-title":"Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery","volume":"99","author":"Bayindir","year":"2010","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejpb.2021.02.015_b0230","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003088-200241030-00006","article-title":"Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer\u2019s type","volume":"41","author":"Hossain","year":"2002","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.ejpb.2021.02.015_b0235","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/17425255.2017.1251580","article-title":"N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects","volume":"13","author":"Minarini","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"12","key":"10.1016\/j.ejpb.2021.02.015_b0240","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1529\/biophysj.107.104042","article-title":"The role of cavitation in liposome formation","volume":"93","author":"Richardson","year":"2007","journal-title":"Biophys. J."},{"issue":"1","key":"10.1016\/j.ejpb.2021.02.015_b0245","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1513\/pats.201007-050RN","article-title":"Anatomy and physiology of the upper airway","volume":"8","author":"Sahin-Yilmaz","year":"2011","journal-title":"Proc. Am. Thorac. Soc."},{"key":"10.1016\/j.ejpb.2021.02.015_b0250","unstructured":"D. Purves, G.J. Augustine, D. Fitzpatrick, L.C. Katz, A.S. LaMantia, J.O. McNamara, S.M. Williams, The olfactory epithelium and olfactory receptor neurons, Neuroscience, seconnd ed., 2001. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK10896\/."},{"issue":"1-2","key":"10.1016\/j.ejpb.2021.02.015_b0255","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijpharm.2005.05.009","article-title":"Effect of cholesterol and temperature on the elastic properties of niosomal membranes","volume":"300","author":"Nasseri","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2021.02.015_b0260","article-title":"Effect of surfactant type, cholesterol content and various downsizing methods on the particle size of niosomes","author":"Nowroozi","year":"2018","journal-title":"Iran. J. Pharm. Res."},{"issue":"5","key":"10.1016\/j.ejpb.2021.02.015_b0265","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.xphs.2018.01.005","article-title":"Surfactant effects on lipid-based vesicles properties","volume":"107","author":"Bnyan","year":"2018","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2021.02.015_b0270","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4103\/2277-9175.178781","article-title":"Effect of different types of surfactants on the physical properties and stability of carvedilol nano-niosomes","volume":"5","author":"Taymouri","year":"2016","journal-title":"Adv. Biomed. Res."},{"issue":"2","key":"10.1016\/j.ejpb.2021.02.015_b0275","first-page":"387","article-title":"A nanomedicine based combination therapy based on QLPVM peptide functionalized liposomal tamoxifen and doxorubicin against Luminal A breast cancer, Nanomedicine Nanotechnology","volume":"12","author":"Wang","year":"2016","journal-title":"Biol. Med."},{"key":"10.1016\/j.ejpb.2021.02.015_b0280","unstructured":"US Food and Drug Administration. Inactive ingredient search for approved drug products. FDA Database: Silver Spring, MD, USA, 2017 [accessed on 24 June 2020]. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/iig\/index.Cfm."},{"key":"10.1016\/j.ejpb.2021.02.015_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/6492953","article-title":"In vitro and in vivo evaluation of niosomal formulation for controlled delivery of clarithromycin","volume":"2016","author":"Shilakari Asthana","year":"2016","journal-title":"Scientifica (Cairo)"},{"key":"10.1016\/j.ejpb.2021.02.015_b0290","doi-asserted-by":"crossref","DOI":"10.1021\/js950474+","article-title":"Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers","author":"Calvo","year":"1996","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejpb.2021.02.015_b0295","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.fshw.2016.03.001","article-title":"In vitro neuroprotective potentials of aqueous and methanol extracts from Heinsia crinita leaves","volume":"5","author":"Oboh","year":"2016","journal-title":"Food Sci. Hum. Wellness."},{"key":"10.1016\/j.ejpb.2021.02.015_b0300","article-title":"Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil","author":"Al Asmari","year":"2016","journal-title":"Drug Des. Devel. Ther."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112100076X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112100076X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:41:32Z","timestamp":1760546492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093964112100076X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":60,"alternative-id":["S093964112100076X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.02.015","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, development and in-vitro\/in-vivo evaluation of intranasally delivered Rivastigmine and N-Acetyl Cysteine loaded bifunctional niosomes for applications in combinative treatment of Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}